Pharma M&A: An Unattractive But Inevitable Reality?
Executive Summary
Pharmaceutical industry mergers have not been a source of sustainable competitive advantage, Wood Mackenzie VP-Life Sciences Clifford Kalb said during the Special Libraries Association Pharmaceutical & Health Technology Division Spring Meeting in Memphis March 28
You may also be interested in...
Bristol May Be An Acquisition Target Following Entry Of Plavix Generics
The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target
Bristol May Be An Acquisition Target Following Entry Of Plavix Generics
The entry of generic competition for Bristol-Myers Squibb/Sanofi-Aventis' blockbuster antithrombotic Plavix could make Bristol an acquisition target
Sanofi-Aventis May Be First In Wave Of National Pharma; Will Swiss Follow?
Sanofi-Synthelabo's merger with Aventis may be the first in a trend towards the creation of national pharma companies that could include the formation of "Pharma Swiss," according to Wood Mackenzie VP-Life Sciences Clifford Kalb